PART I Overview We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform. This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases. Our masking strategy is des...
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-107146 | EDGAR | 99K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034575 | EDGAR | — |
| 2024-03-11 | 2023-12-31 | 0000950170-24-029191 | EDGAR | — |
| 2023-03-27 | 2022-12-31 | 0000950170-23-009991 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002519 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001564590-21-008081 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007395 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001564590-19-004890 | EDGAR | — |
| 2018-03-07 | 2017-12-31 | 0001564590-18-004727 | EDGAR | — |
| 2017-03-02 | 2016-12-31 | 0001564590-17-003229 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-337950 | EDGAR | — |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269477 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104991 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-068511 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123249 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093865 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055588 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060201 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039761 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019654 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023190 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014737 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-338009 | EDGAR | — |
| 2026-07-27 | 0001193125-26-316929 | EDGAR | — |
| 2026-03-19 | 0001193125-26-115958 | EDGAR | 29K words |
| 2026-03-16 | 0001193125-26-107152 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269533 | EDGAR | — |
| 2025-08-13 | 0001193125-25-179463 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105053 | EDGAR | — |
| 2025-06-13 | 0001193125-25-140739 | EDGAR | — |
| 2025-05-28 | 0001193125-25-129470 | EDGAR | — |
| 2025-05-13 | 0001193125-25-118805 | EDGAR | — |
210 total filings indexed. 178 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001501989 |
| Ticker | CTMX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cytomx.com |
| Listed | 2015-10-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CTMX (~200 tokens, structured JSON with cryptographic provenance)